Active	Status	Sponsor type	Region	Phase	Filter
3 Active 7 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
pertuzumab zuvotolimod (SBT6050) / ARS Pharma
NCT04460456: A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors Interim data in combination with SBT6050 for advanced or metastatic HER2-expressing solid tumor Sep 2021 - Sep 2021: Interim data in combination with SBT6050 for advanced or metastatic HER2-expressing solid tumor	Active, not recruiting	1	58	US, RoW	SBT6050, pembrolizumab, Cemiplimab	Silverback Therapeutics	HER2 Positive Solid Tumors	12/22	12/22
Neffy (epinephrine) / ARS Pharma, Neurelis
NCT05363670: Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma	Completed	2	18	US	ARS-1, Albuterol MDI, Placebo	ARS Pharmaceuticals, Inc.	Asthma	02/24	02/24
NCT05496465: Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares	Completed	2	24	US	ARS-1, Placebo	ARS Pharmaceuticals, Inc.	Urticaria	02/24	02/24
SBT8230 / ARS Pharma
No trials found
SBT6290 / ARS Pharma
No trials found
TGFβR Antagonist Conjugates / ARS Pharma
No trials found
Undisclosed TLR8 agonist ADC / ARS Pharma
No trials found